Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma

Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Journal of Clinical Oncology (Impact Factor: 17.88). 02/2010; 28(9):1606-10. DOI: 10.1200/JCO.2009.25.5356
Source: PubMed

ABSTRACT With whole-body magnetic resonance imaging (wb-MRI), almost the whole bone marrow compartment can be examined in patients with monoclonal plasma cell disease. Focal lesions (FLs) detected by spinal MRI have been of prognostic significance in symptomatic multiple myeloma (sMM). In this study, we investigated the prognostic significance of FLs in wb-MRI in patients with asymptomatic multiple myeloma (aMM).
Wb-MRI was performed in 149 patients with aMM. The prognostic significance of the presence and absence, as well as the number, of FLs for progression into sMM was analyzed.
FLs were present in 28% of patients. The presence per se of FLs and a number of greater than one FL were the strongest adverse prognostic factors for progression into sMM (P < .001) in multivariate analysis. A diffuse infiltration pattern in MRI, a monoclonal protein of 40 g/L or greater, and a plasma cell infiltration in bone marrow of 20% or greater were other adverse prognostic factors for progression-free survival in univariate analysis.
We recommend use of wb-MRI for risk stratification of patients with asymptomatic multiple myeloma.

Download full-text


Available from: Stefan Delorme, Jun 30, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone disease is the major feature of multiple myeloma (MM). Imaging is required for correct staging, in the follow-up after treatment and, as recently highlighted, is predictor of prognosis. In the near future, whole-body X-Ray may be replaced by more sensitive techniques, such as whole-body low-dose computerized tomography (CT). Magnetic resonance imaging (MRI) is the gold standard method for assessing bone marrow infiltration of the spine, predicting the risk of vertebral fracture and distinguishing between benign and malignant osteoporosis. Positron emission tomography (PET) with CT (PET/CT) provides important information about the extent of whole-body disease, including soft tissue masses, and is the best tool to distinguish between active or inactive disease after therapy. Both MRI and PET/CT are predictors of clinical outcome. A prospective use of these newer imaging techniques in both clinical trials and clinical practice may help optimize MM management in the near future.
    British Journal of Haematology 08/2012; 159(5). DOI:10.1111/bjh.12007 · 4.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone marrow plasma cell infiltration is a crucial parameter of disease activity in monoclonal plasma cell disorders. Until now, the only way to quantify such infiltration was bone marrow biopsy or aspiration. Diffusion-weighted imaging (DWI) is a magnetic resonance imaging-technique that may mirror tissue cellularity by measuring random movements of water molecules. To investigate if DWI is capable of assessing bone marrow cellularity in monoclonal plasma cell disease, we investigated 56 patients with multiple myeloma or monoclonal gammopathy of undetermined significance, and 30 healthy controls using DWI of the pelvis and/or the lumbar spine. In 25 of 30 patients who underwent biopsy, bone marrow trephine and DWI could be compared. Of the patients with symptomatic disease 15 could be evaluated after systemic treatment. There was a positive correlation between the DWI-parameter apparent diffusion coefficient (ADC) and bone marrow cellularity as well as micro-vessel density (P<0·001 respectively). ADC was significantly different between patients and controls (P<0·01) and before and after systemic therapy (P<0·001). In conclusion, DWI enabled bone marrow infiltration to be monitored in a non-invasive, quantitative way, suggesting that after further investigations on larger patient groups this might become an useful tool in the clinical work-up to assess tumour burden.
    British Journal of Haematology 06/2011; 153(6):721-8. DOI:10.1111/j.1365-2141.2011.08658.x · 4.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die häufigsten Formen monoklonaler Plasmazellerkrankungen sind die monoklonale Gammopathie unklarer Signifikanz (MGUS) und das multiple Myelom (MM). Die Prävalenz beider Erkrankungen nimmt mit dem Alter zu und liegt für die MGUS bei über 70-Jährigen bei 3–5%. Für das MM sind 4–5/100.000 Neuerkrankungen pro Jahr beschrieben. Während es sich bei der MGUS lediglich um eine nichttherapiebedürftige Laborveränderung handelt, die ein mit 1% pro Jahr leicht erhöhtes Risiko hat, in eine maligne Erkrankung überzugehen, wird das MM in ein symptomatisches, therapiepflichtiges und ein asymptomatisches nichttherapiepflichiges Stadium unterschieden. Die Kriterien für die Therapieentscheidung sind folgende als Endorganschäden definierte Befunde: 1. Knochendestruktion und Hyperkalzämie, 2. Anämie und 3. Nierenfunktionseinschränkung. Die wichtigsten Prognosefaktoren beim MM sind das β2-Mikroglobulin und das Albumin im Serum sowie zytogenetische Veränderungen der monoklonalen Plasmazellen. The most common forms of monoclonal plasma cell dyscrasia are monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). The prevalence of both diseases increases with age; MGUS occurs in 3–5% of individuals older than 70 years and the incidence of multiple myeloma is 4–5/100,000 per year. While MGUS is an asymptomatic laboratory finding which does not need therapeutic intervention, an asymptomatic and a symptomatic stage can be distinguished in MM. MGUS progresses into a malignant plasma cell disease with a incidence of 1% per year. Indications for treatment are defined by the following parameters known as end organ damage: 1) bone disease and hypercalcemia, 2) anemia and 3) renal impairment. The most important prognostic factors are beta-2 microglobulin and albumin levels in serum as well as cytogenetic abnormalities of the monoclonal plasma cells. SchlüsselwörterMGUS-Multiples Myelom-Epidemiologie-Stadieneinteilung-Differenzialdiagnose KeywordsMGUS-Multiple myeloma-Epidemiology-Staging-Differential diagnosis
    Der Onkologe 03/2010; 16(3):225-231. DOI:10.1007/s00761-010-1792-z · 0.13 Impact Factor